Skip to main content

Mar Tintore Subirana

I am a Neurologist and Head of Care at the Centre d'Esclerosi Multiple de Catalunya (Cemcat) of the Neurology/Neuroimmunology service of the Vall d'Hebron University Hospital. Since June 2023 I have been Head of Section at the Centre d'Esclerosi Multiple de Catalunya (Cemcat) of the Neurology/Neuroimmunology service of the Vall d'Hebron University Hospital. Since 2021 I have been a professor of Neurology at the University of Vic-Central University of Catalonia (UVic-UCC).

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Clinical neuroimmunology
General Hospital
Responsable Assistencial
Multiple Sclerosis Centre of Catalonia

Mar Tintore Subirana

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Clinical neuroimmunology
General Hospital
Responsable Assistencial
Multiple Sclerosis Centre of Catalonia

I am a Neurologist and Head of Care at the Centre d'Esclerosi Multiple de Catalunya (Cemcat) of the Neurology/Neuroimmunology service of the Vall d'Hebron University Hospital. Since June 2023 I have been Head of Section at the Centre d'Esclerosi Multiple de Catalunya (Cemcat) of the Neurology/Neuroimmunology service of the Vall d'Hebron University Hospital. Since 2021 I have been a professor of Neurology at the University of Vic-Central University of Catalonia (UVic-UCC).

I have developed in particular the study of prognostic factors, multiple sclerosis of the child and adolescent, as well as family planning in women with multiple sclerosis. I am currently a member of the Advisory Ethics Committee (CEA) of the Vall d'Hebron University Hospital.

I have published more than 369 articles in national and international journals and am a regular reviewer of indexed journals both national and international. My factor H is currently 60 and until April 2026 my work has received 26,854 citations.

Projects

Neuroimmunologia clínica

IP: Mar Tintore Subirana
Collaborators: Miriam Izquierdo Sans, Andreu Vilaseca Jolonch
Funding agency: Instituto de Salud Carlos III
Funding: 65000
Reference: CM22/00247
Duration: 01/03/2023 - 28/02/2025

SGR-Cat 2021: Neuroimmunologia Clínica

IP: SGR-Cat 2021: Neuroimmunologia Clínica
Collaborators: Carlos Nos Llopis, SGR-Cat 2021: Neuroimmunologia Clínica, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Andrea Serrano Mascarós, Margarida Capell Maymo, Samuel Sánchez Pous, Elisenda Anglada Clofent, Montserrat Aroca Alsina, Sergio Cabello, Carmen Tur Gomez, Gabriel Ig Camiña Rodríguez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, Mar Tintore Subirana, M Jesus Arevalo Navines, Edwin Roger Meza Murillo, Augusto Cesar Sao Aviles, Miguel Angel Robles Sanchez, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Gaizka Loyola Sanmillan, Mireia Resina Salles, Angela Vidal Jordana, Lucía Gutiérrez Ruiz, Ana Zabalza de Torres, Sergio Vergara Ruiz, Rafael Garcia Merida, Luciana Midaglia Fernandez, Alvaro Cobo Calvo, Neus Mongay Ochoa, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Andres Miguez Gonzalez, Mireia Castillo Juarez, Rucsanda Pinteac, Nicolás Miguel Fissolo
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00782
Duration: 01/01/2022 - 30/06/2025

Estudio de comorbilidad y de inmunogenicidad vacunal en una cohorte prospectiva de pacientes con primeros brotes sugestivos de Esclerosis Múltiple

IP: Susana Otero Romero
Collaborators: Juliana Esperalba Esquerra, Mar Tintore Subirana, Laia Pinos Tella, Luciana Midaglia Fernandez, Sonia Maria Uriona Tuma, Sonia Maria Uriona Tuma
Funding agency: Instituto de Salud Carlos III
Funding: 105270
Reference: PI19/01606
Duration: 01/01/2020 - 30/06/2024

Rol of optical coherence tomography in predicting treatment response

IP: Mar Tintore Subirana
Collaborators: Miriam Izquierdo Sans
Funding agency: ECTRIMS
Funding: 55000
Reference: ECTRIMS/HHRR/2019/CARDENAS
Duration: 14/09/2019 - 14/11/2020

Related news

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Francisco José Aparicio Serrano

Francisco José Aparicio Serrano

Research technician
Clinical Neuroimmunology
Read more
Marta Calvo Aguilar

Marta Calvo Aguilar

Research technician
Peripheral Nervous System
Read more
Yeika Adelina Perez Dotel

Yeika Adelina Perez Dotel

Research technician
Rheumatology
Read more
Olivia Casbas Recuenco

Olivia Casbas Recuenco

Predoctoral researcher
Diabetes and Metabolism
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.